There is more to cannabis than THC and CBD. As our understanding (and commercialization) of cannabis evolves, new compounds like CBG, delta-8-THC, THCv, and others are coming onto the scene. These various "minor" cannabinoids, however, bring with them a host of new issues.
NCIA's Cannabis Manufacturing Committee and Scientific Advisory Committee are collaborating on a series of #IndustryEssentials webinars over the next few months which will explore these issues with various subjects ranging from basic and advanced overviews of these molecules, regulatory recommendations, risk management and compliance concerns all the way to consumer and manufacturer safety.
The panel will kick off this series by introducing and framing the myriad regulatory, scientific, linguistic, and ethical issues that come with the rise of minor, novel, and synthetic cannabinoids.
• Understand the role of minor, novel, and synthetic cannabinoids in the cannabis industry and the unique issues relating to their current status.
At the conclusion of the discussion they’ll be hosting a moderated Q&A session so don’t miss your chance to participate in this interactive educational experience with leading manufacturing, biochemical, and legal professionals from the hemp and cannabis industries.
*15-Minute Introductory Session*
Acquire the foundational knowledge needed to dive deep into this session by watching this introductory video on Minor, Novel and Synthetic Cannabinoids.
Learn More: http://bit.ly/3GnIJN4
Members of NCIA's Cannabis Manufacturing Committee, walk you through the categories of compounds, outside of the commonly known big two - THC and CBD, and explain what is known about them along with what the industry can do to move forward to provide safe products to consumers.